A company called Procept BioRobotics makes a special machine that helps fix problems with pee. The people who use this machine, the doctors or surgeons, really like it and want to use it more. So, many people are buying shares of this company because they think it will make them money in the future. This is making the price of these shares go up. Read from source...

1. The article title is misleading and sensationalist, implying that the company's shares are higher today because of strong surgeon interest, without providing any evidence or data to support this claim. A more accurate title would be "Procept BioRobotics Shares Are Higher Today, CEO Touts 'Strong Surgeon Interest', but Why?"
2. The article quote from the CEO is vague and unsubstantiated, stating that the company is well positioned to deliver outsized revenue growth driven by outstanding real-world clinical outcomes of Aquablation Therapy, without providing any specific details or data on these outcomes or how they translate into market share or profitability.
3. The article mentions the largest and most tenured capital sales team in the company's history, but does not provide any information on how this has impacted the company's performance or growth compared to previous periods or competitors. Additionally, it is unclear what criteria are used to measure the size and tenure of the sales team, and whether these factors are relevant or meaningful for investors.
4. The article reports that there is strong surgeon interest leading to rapid adoption within urology practices, but does not provide any data or evidence on how many surgeons have adopted Aquablation Therapy, how this compares to other treatments or competitors, and what the potential market size and demand are for this therapy.
5. The article does not include any critical analysis or contextual information on the company's financial performance, valuation, risks, challenges, opportunities, or outlook, which would be important for investors to make informed decisions about the company's prospects and attractiveness as an investment.